Trials / Completed
CompletedNCT03118817
Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers
A Single-arm, Open-label, Multi-center, Phase I Expansion Study Evaluating the Efficacy and Safety of HM95573 Monotherapy in Patients With BRAF, KRAS or NRAS Mutation-positive Solid Cancers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 65 (actual)
- Sponsor
- Hanmi Pharmaceutical Company Limited · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the anti-tumor efficacy and safety of single agent HM95573 administered in patients with solid tumors harboring mutations in either BRAF, KRAS or NRAS gene.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HM95573 | Dose: 450 mg BID Regimen: twice daily (BID), continuous dosing Duration: until progression disease or unacceptable toxicity develops |
Timeline
- Start date
- 2017-05-19
- Primary completion
- 2020-02-04
- Completion
- 2020-02-04
- First posted
- 2017-04-18
- Last updated
- 2020-08-10
Locations
7 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03118817. Inclusion in this directory is not an endorsement.